Research Paper Volume 16, Issue 5 pp 4841—4861
HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung adenocarcinoma
Figure 8. The predictive value of HOXC9 and TME markers for LUAD patients treated with PD-1 blockade plus chemotherapy. (A) Diagram of clinical samples selection and analysis. (B) IHC analysis of 5 proteins based on samples from 4 patients with different level of HOXC9. (C) The different distributions of responder population under 5 types of TME marker. (D) Analysis of predictive value of combination of HOXC9- and other markers. (E) PFS and OS analysis based on different status of markers. (F) PFS and OS analysis based on different combinations. (*P<0.05, **P<0.01, ***P<0.001).